Stock Information

• Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction - Slideshow
  Thu, Jun 25, 2026 2:32 PM
• Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript
  Thu, Jun 25, 2026 2:32 PM
• Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Raises Price Target to $75
  Thu, Jun 25, 2026 1:46 PM
• Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk
  Thu, Jun 25, 2026 12:25 PM
• Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $129
  Thu, Jun 25, 2026 12:10 PM
• HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $130
  Thu, Jun 25, 2026 7:54 AM
• Ionis Pharmaceuticals Announces License Agreement With Recordati For Zilganersen In Alexander Disease In All Countries Outside The US For $30M Upfront Payment
  Thu, Jun 25, 2026 3:27 AM
• FDA Approves First Treatment Shown To Reduce The Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
  Wed, Jun 24, 2026 11:46 AM

Financial data not available